


RESEARCH

Open Access



Novel compound heterozygous mutations in plasminogen (p.Gly568Arg/p.Ala620Thr) impair protein structure and function in type II deficiency: mechanistic insights into a hereditary thrombogenic disorder

Yifan Lu¹, Fengjiao Wang¹, Dandan Yu¹, Haixiao Xie¹, Yanhui Jin¹, Mingshan Wang¹ and Lihong Yang^{1*} 

Abstract

Background Hereditary plasminogen (PLG) deficiency represents an extremely rare autosomal recessive disorder characterized by impaired fibrinolytic capacity resulting from diminished PLG enzymatic activity. In this study, we identify and characterize a novel compound heterozygous PLG mutation clinically associated with cerebral infarction. Our findings demonstrate that structural conformational alterations in the mutation PLG protein disrupt normal fibrinolytic pathway function.

Methods In this study, the proband presented at the First Affiliated Hospital of Wenzhou Medical University with a chief complaint of “left-sided limb weakness lasting for two days.” PLG activity (PLG: A) and PLG antigen (PLG: Ag) levels were measured in the proband and eight family members spanning three generations using the chromogenic substrate assay (CSA) and enzyme-linked immunosorbent assay (ELISA), respectively. The genetic mutation site was identified through direct DNA sequencing. Bioinformatics software was employed to analyze the conservation and potential pathogenicity of the mutation site. A mutation protein model was constructed to investigate structural alterations in the protein before and after the mutation. Furthermore, a recombinant plasmid expression vector was developed, and the in vitro expression of the recombinant PLG protein was evaluated using real-time quantitative PCR (RT-qPCR), ELISA, and Western blot (WB) analysis.

Results The proband had a significantly reduced PLG: A to 27%, but the PLG: Ag level was normal at 103%, and was diagnosed with type II plasminogen deficiency (dysplasminogenemia). Sanger sequencing identified compound heterozygous missense mutations in the PLG gene: c.1702G > A (p.Gly568Arg) in exon 14 and c.1858G > A (p.Ala620Thr) in exon 15. Both mutation sites are highly conserved across species, and four independent bioinformatics tools consistently predicted pathogenic effects. Molecular modeling demonstrated that the p.Gly568Arg substitution causes steric hindrance through side chain elongation and establishes a new hydrogen

*Correspondence:
Lihong Yang
ylh91@163.com

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

bond with Leu686; p.Ala620Thr destabilized the catalytic triad (His603-Asp646-Ser741). In vitro functional assays, including RT-qPCR, ELISA, and WB analysis, confirmed that neither mutation significantly altered the expression level of mRNA, protein biosynthesis and secretion. However, the PLG: A/PLG: Ag ratio in the media was markedly reduced compared to wild-type controls.

Conclusions We report the first case worldwide of a novel p.Gly568Arg mutation in the PLG gene, which coexists with the p.Ala620Thr mutation in a compound heterozygous form. Structural and functional analyses indicate that although the transcription, protein synthesis and secretion of the PLG gene are not affected, these two mutations specifically impair the catalytic activity of the PLG protein through different conformational changes. This expands the mutation spectrum and clarifies a novel thrombosis mechanism in type II PLG deficiency.

Keywords PLG, Hereditary PLG deficiency, In vitro expression, Thrombus formation

Introduction

The fibrinolytic system serves as a crucial regulatory network for vascular homeostasis, primarily through fibrin degradation to prevent pathological thrombosis [1]. This system comprises plasminogen (PLG), its activators (tissue-type PLG activator [t-PA] and urokinase-type PLG activator [u-PA]), inhibitors and α 2-antiplasmin), and fibrin substrates - collectively forming a precisely balanced feedback loop [2, 3]. PLG functions as the fibrinolytic system's core zymogen, tPA/uPA-mediated activation converts PLG to plasmin, which cleaves fibrin and extracellular matrix (ECM) proteins [4]. Furthermore, plasmin proteolytically processes inflammatory mediators, thereby modulating immune responses [5], and promotes epithelial migration via specific receptor interactions, which facilitates wound repair [6].

Hereditary PLG deficiency comprises a spectrum of disorders caused by pathogenic PLG gene mutations, characterized by either quantitative deficiency or dysfunctional PLG protein. This impairment disrupts fibrinolytic homeostasis, resulting in a rare prothrombotic state with an estimated prevalence of 1.6 cases per million individuals [7]. The PLG gene comprises 19 exons and 18 introns [8]. The precursor protein encoded by this gene consists of 810 amino acids and ultimately gives rise to the mature PLG protein. Structurally, PLG consists of three primary domains: an N-terminal peptide (NTP), five kringle domains (K1-K5), and a C-terminal serine protease (SP) domain [9]. PLG specifically binds to fibrin via its kringle domains. The Arg561-Val562 site within the SP domain functions as a critical site for proteolytic activation. Following cleavage at this site, PLG is activated into catalytically active plasmin, which subsequently mediates efficient fibrin degradation [10]. Current evidence indicates that pathogenic mutations are mainly concentrated in the Kringles domain and the SP domain. Mutations in these specific regions lead to different clinical phenotypes. Mutations in the Kringles domain, such as p.Lys38Glu, usually result in local fibrin deposition, presenting as ligneous conjunctivitis. Mutations in the SP domain, such as p.Arg561His, impair

systemic fibrinolysis, leading to thrombotic events or organ fibrosis [8, 11].

We conducted an integrated genetic and functional analysis of PLG mutations in a proband presenting with ischemic stroke and reduced PLG: A activity, along with affected family members. This study elucidated the possible molecular mechanisms underlying PLG deficiency and provides a foundation for refining diagnostic approaches and developing targeted therapeutic strategies.

Materials and methods

Clinical evaluation and coagulation profiling

We collected clinical data from the proband and family members. Venous blood was anticoagulated with 3.2% sodium citrate (9:1 v/v) and processed within 2 h. Following centrifugation (1,500×g, 15 min, 22°C), platelet-poor plasma (PPP) was aliquoted and stored at -80°C pending analysis. The buffy coat was isolated for genomic DNA extraction. PLG: A, protein C activity (PC: A), and anti-thrombin III activity (AT: A) were measured using chromogenic substrate assay (CSA) on a STA-R-Max analyzer (Diagnostica Stago, France). Protein S activity (PS: A) was determined by clotting assay on the same platform, while PLG antigen (PLG: Ag) levels were quantified using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Jianglai Biotechnology, China). All analyses are performed in duplicate following both Clinical and Laboratory Standards Institute (CLSI) guidelines and the manufacturer's protocols.

Gene analysis

Genomic DNA was extracted from peripheral blood leukocytes using the TIANamp Genomic DNA Kit (DP304; Tiangen Biotech, Beijing, China). For PLG gene analysis (Gene ID: 5340; RefSeq NM_000301.3), we designed 19 primer pairs encompassing all exons and flanking splice junctions (\pm 50 bp) according to published methodology [12]. Polymerase chain reaction (PCR) amplification was performed under optimized conditions, with subsequent bidirectional Sanger sequencing using an

ABI 3730xl Genetic Analyzer (Applied Biosystems). All primers (HPLC-purified) were commercially synthesized (Shanghai Saiheng Biotechnology). Sequence traces were analyzed with Chromas Pro (Technelysium) and aligned to the PLG reference sequence (NCBI RefSeq NG_016200.1) via Primer-BLAST (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>). Mutations identified in the proband were classified according to American College of Medical Genetics and Genomics (ACMG) guidelines and verified in family members through targeted sequencing.

In Silico analysis

Pathogenicity predictions for identified mutations was performed using six established prediction algorithms: MutationTaster (<https://www.mutationtaster.org/>), SIFT (<https://sift.bii.a-star.edu.sg/>), PROVEAN (<https://provean.jcvi.org/>), FATHMM (<https://fathmm.biocompute.org.uk/>), CADD (<https://cadd.gs.washington.edu/score>) and REVEL (<https://asia.ensembl.org/Tools/VEP>). Evolutionary conservation was assessed via Clustal X 2.1 multiple sequence alignment of homologous RefSeq sequences (<https://www.ncbi.nlm.nih.gov/nucore/>). PyMOL (v2.7) modeling revealed mutation-specific structural changes. Furthermore, the population-based allele frequencies for both mutations were obtained from the gnomAD database.

Construction of recombinant PLG expression vector

The pCDH-copGFP-T2A-Puro plasmid (System Biosciences, USA) was used for PLG overexpression. Primers were designed based on the full-length PLG complete coding sequence (CDS), and the PCR product was gel-purified, digested with XbaI/NotI (Takara Bio, Japan), and ligated into the linearized vector. Site-directed mutagenesis was performed using the Mut Express II Fast Mutagenesis Kit V2 (Vazyme) with custom-designed primers. All constructs (wild-type and mutation) were verified by bidirectional Sanger sequencing. Human embryonic kidney 293T (HEK293T) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen), 100 U/ml penicillin, and 100 µg/ml streptomycin (Beyotime) under standard conditions. For transfection, cells at 70–80% confluency were transfected with plasmid constructs using Lipofectamine 5000 (Biodai Biotechnology, China) according to the manufacturer's protocol. After 48 h, cells and conditioned medium were collected. The conditioned medium was concentrated using Amicon Ultra-30 K centrifugal filters (Millipore; 4,000 ×g, 30 min).

Total RNA extraction and quantitative real-time PCR (RT-qPCR)

Total RNA was extracted from transfected cells using RNAiso Plus (Takara, Japan). Complementary DNA (cDNA) was synthesized with HiScript II Q RT SuperMix (Vazyme), followed by RT-qPCR using Taq Pro Universal SYBR qPCR Master Mix (Vazyme) on a QuantStudio™ 5 system (Thermo Fisher Scientific). cDNA was synthesized with HiScript II Q RT SuperMix (Vazyme, China) on a QuantStudio™ 5 system (Thermo Fisher Scientific, America). GAPDH served as the endogenous control. Wild-type and mutation PLG mRNA expression levels were quantified using the comparative Ct ($2^{-\Delta\Delta Ct}$) method (Supplementary Table 1).

Western blot (WB) and enzyme-linked immunosorbent assay (ELISA)

The plasmid was transfected into the medium containing 10% fetal bovine serum and cultured for 48 h. The cells and media were collected for analysis. Cell proteins were extracted using RadioImmunoPrecipitation Assay (RIPA) Buffer lysis buffer supplemented with phenylmethylsulfonyl fluoride (PMSF), while supernatants were concentrated by centrifugal ultrafiltration. Proteins were denatured, separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to polyvinylidene fluoride (PVDF) membranes. After blocking with 5% skim milk in Tris-buffered saline with Tween-20 (TBST) for 2 h at room temperature, membranes were incubated overnight at 4 °C with primary antibodies: anti-PLG (1:2000; Proteintech, China) and anti-GAPDH (1:2000; Proteintech, China). Following washes, membranes were incubated with HRP-conjugated goat anti-rabbit IgG (1:5000; Beyotime, China) for 1 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence (ECL) detection kit (Yasen Biotechnology) and quantified by densitometry. The protein bands were visualized using an ECL ultra-sensitive detection kit (Yasen Biotechnology, China) and quantified by densitometry. PLG: Ag levels in cell lysates and supernatants were quantified by ELISA (Jianglai Biotechnology, China). PLG: A in supernatants was measured using chromogenic substrate assays on a STA-R Max analyzer. Specific activity was calculated as the PLG: A/PLG: Ag ratio and normalized to wild-type PLG (100%).

Results

Clinical investigation, laboratory findings, and PLG mutations

This study examined an eight-member, three-generation consanguineous family (Fig. 1). The 60-year-old female proband presented to our institution with two-day persistent left hemiplegia. Brain Magnetic resonance




Fig. 1 Pedigree of the PLG-deficient family

imaging(MRI) demonstrated multiple acute ischemic infarcts involving the right frontal, parietal, temporal, occipital, and insular lobes (Fig. 2). Thromboelastography (TEG) revealed a hypercoagulable state (Supplementary Fig. 1), prompting treatment with dual antiplatelet therapy, atorvastatin for dyslipidemia, and neuroprotective

butylphthalide, which stabilized her condition. Coagulation studies showed markedly reduced PLG: A (27%) in the proband despite normal antigen levels. Her two sons and grandson exhibited approximately 50% of normal PLG: A with preserved antigen levels, while other family members showed normal coagulation parameters. After comprehensive screening ruled out common thrombotic causes, targeted genetic analysis was pursued, which identified two heterozygous missense mutations in the proband's PLG gene: c.1702G>A (p.Gly568Arg) in exon 14 and c.1858G>A (p.Ala620Thr) in exon 15 (Fig. 3). Segregation analysis revealed each son and grandson carried one mutation (either p.Gly568Arg or p.Ala620Thr). All unaffected family members had wild-type genotypes (Table 1).

In silico analysis

Six computational prediction tools (SIFT, PolyPhen-2, MutationTaster, PROVEAN, CADD, REVEL) consistently classified both p.Gly568Arg and p.Ala620Thr mutations as pathogenic (Table 2). Cross-species alignment demonstrated complete evolutionary conservation of both residues across seven representative species (Fig. 4). Structural modeling indicated that the p.Gly568Arg disrupted the Gly568-Trp772-Pro683 hydrogen bond network while forming a new interaction with Leu686; the




Fig. 2 Brain MRI findings. **A:** DWI head MRI; **B:** ADC head MRI; **C:** T2-weighted head MRI; **D:** Flair head MRI; **E, F:** T1-weighted head MRI




Fig. 3 Direct sequencing results of the proband's genes. **Ⓐ**: Direct sequencing of the c.1858G>A mutant type. **Ⓑ**: Direct sequencing of the c.1858G>A wild type. **Ⓒ**: Direct sequencing of the c.1702G>A mutant type. **Ⓓ**: Direct sequencing of the c.1702G>A wild type. The black arrows indicate the mutation sites

Table 1 Clinical and coagulation profiles in a PLG-deficient family

| Family members | PLG: A(%) | PLG: Ag(%) | PC: A(%) | PS: A(%) | AT: A(%) | Mutation type | Clinical manifestations |
|-------------------------|-----------|------------|----------|----------|----------|----------------------------|-------------------------|
| Proband(I1) | 27 | 103 | 106 | 97 | 99 | p.Ala620Thr p.Gly568Arg | Acute Ischemic Stroke |
| Husband(I2) | 93 | 120 | 111 | 133 | 103 | Wild type | asymptomatic |
| eldest son's wife(II 1) | 107 | 123 | 93 | 129 | 115 | Wild type | asymptomatic |
| Eldest son(II 2) | 54 | 116 | 107 | 104 | 107 | p.Ala620Thr | asymptomatic |
| Youngest son(II 3) | 42 | 104 | 97 | 113 | 105 | p.Gly568Arg | asymptomatic |
| Grandson(III1) | 55 | 119 | 95 | 104 | 109 | p.Ala620Thr | asymptomatic |
| Reference range | 75~140 | 50~150 | 70~130 | 65~135 | 96~118 | / | / |

PLG: A: plasminogen activity; PLG: Ag: plasminogen antigen; PC: A: protein C activity; PS: A: protein S activity; AT: A: antithrombin activity

p.Ala620Thr introduced steric constraints through threonine side-chain extension(Fig. 5). The Ala620Thr variant was observed at an allele frequency of 0.0509% [gnomAD v4.1.0 (GRCh38)], in contrast to the Gly568Arg variant, which is novel (absent from gnomAD).

In vitro expression study of transfected HEK cells
RT-qPCR analysis revealed no statistically significant differences in mRNA expression levels between PLG-WT and the mutations (Fig. 6). WB analysis demonstrated that the protein bands of PLG-A620T and PLG-G568R mutations in both cell lysates and media showed no

Table 2 Pathogenicity prediction of genetic mutations

| Mutation | MutationTaster | SIFT | PROVEAN | FATHMM | CADD | REVEL |
|-------------|----------------|-------|---------|--------|------|-------|
| p.Gly568Arg | 1.000 | 0.002 | -5.85 | -1.85 | 28.9 | 0.690 |
| p.Ala620Thr | 1.000 | 0.088 | -2.77 | -3.76 | 29.5 | 0.797 |

Note: The prediction value range of MutationTaster is 0 to 1, and the closer to 1, the more likely it is to be pathogenic; the score range of SIFT is 0 to 1, and a score < 0.05 is predicted to be deleterious; the predicted result score range of PROVEAN is -14 to 14, with a threshold of -2.5, and a score of -14 to 2.5 is predicted to be deleterious, and the smaller the score, the more deleterious it is; a score < 0 of FATHMM is predicted to be deleterious; A CADD score of ≥ 10 suggests potential harm, ≥ 20 (top 1%) indicates likely harm, and ≥ 30 (top 0.1%) indicates highly likely harm. A REVEL score > 0.75 is highly likely to be pathogenic, 0.6–0.75 is likely to be pathogenic; 0.4–0.6 is undetermined and requires combination with other methods; < 0.4 is inclined to be benign, 0.15–0.4 is likely to be benign, and < 0.15 is highly likely to be benign




Fig. 4 Conservation analysis of p.Gly568Arg and p.Ala620Thr across different species.(★, :, and · indicate that the amino acid site is completely conserved, highly conserved, and weakly conserved, respectively)




Fig. 5 Protein spatial model structure diagrams of p.Gly568Arg and p.Ala620Thr. (A) The p.Ala620Thr wild-type PLG protein molecular model; (B) The p.Ala620Thr mutant PLG protein molecular model; (C) The p.Gly568Arg wild-type PLG protein molecular model; (D) The p.Gly568Arg mutant PLG protein molecular model




Fig. 6 The relative expression levels of mRNA of wild-type and mutant recombinant plasmids ("ns" indicates no significant difference, $p > 0.05$)

significant differences compared to PLG-WT (Fig. 7). ELISA results indicated that in cell lysates, PLG: Ag levels were $88.7\% \pm 2.6\%$ for PLG-A620T and $93.2\% \pm 1.8\%$ for PLG-G568R; in media, the levels were $98.7\% \pm 4.9\%$ for PLG-A620T and $101.2\% \pm 5.1\%$ for PLG-G568R. The PLG: Ag content in the cell lysates or media of the two

mutations was not statistically significantly different from that of PLG-WT. However, both mutations exhibited significantly reduced PLG: A/PLG: Ag ratios compared to PLG-WT, suggesting preserved secretory function but impaired enzymatic activity (Supplementary Fig. 2; Fig. 8).

Discussion

Hereditary PLG deficiency can be classified into two subtypes: Type I (reduced activity and antigen levels) typically causes ligneous conjunctivitis, while Type II (reduced activity with normal antigen levels) predisposes to venous thromboembolism [11, 13]. We report a Type II case in a 60-year-old woman presenting with acute ischemic stroke, showing characteristic laboratory findings (27% activity with normal antigen levels). Genetic testing revealed two pathogenic PLG mutations (p.Gly568Arg and p.Ala620Thr) meeting ACMG criteria (PS1/PM2/PP3/PP4) [14], absent in 100 controls, with autosomal recessive disorder. This case demonstrates the classic Type II triad: selective activity deficiency, thrombotic predisposition, and confirmed pathogenic mutations.

The p.Ala620Thr mutation was first identified by N Aoki et al. in 1978 [15], whereas p.Gly568Arg is a novel




Fig. 7 The WB experimental protein expression results of PLG protein in HEK293T cells. (The upper band is the target protein band, and the lower band is the internal reference protein GAPDH band.)




Fig. 8 Quantitative analysis of PLG protein in the media was conducted by ELISA. ("ns" indicates no significant difference, $p > 0.05$; "****" indicates a significant difference, $p < 0.001$). PLG: A (brown bars); PLG: Ag (blue bars); and PLG: A/PLG: Ag (grey bars)

pathogenic mutation. Both were predicted to be pathogenic by multiple bioinformatics tools and are located at highly evolutionarily conserved residues that are crucial for the structure and function of PLG. Structural modeling indicates p.Ala620Thr forms three additional hydrogen bonds with the catalytic triad (His603-Asp646-Ser741), potentially distorting the active site [16], whereas p.Gly568Arg adjacent to the t-PA/u-PA cleavage site (Arg561-Val562) creates steric hindrance through a new hydrogen bond with Leu686, impairing proteolytic activation [9, 17]. The research by Chen et al. [17] demonstrated that the p.Ala620Thr mutation would interfere with the normal spatial conformation of the protein, forming structurally abnormal proteins and weakening the catalytic activity of plasminogen. This is consistent with the case and conclusion discussed in this article. This confirms that the mutation may significantly impair the catalytic activity of the protein, thereby leading to hereditary plasminogen deficiency. The compound heterozygous mutation status observed in the proband demonstrated a synergistic effect, as evidenced by a markedly reduced PLG: A level compared to that of heterozygous relatives carrying only a single mutation. This synergistic interaction resulted in severely impaired fibrinolytic activity, thereby significantly elevating the risk of thrombosis.

This study comprehensively characterized the molecular pathogenesis of type II PLG deficiency through parallel investigation of human mutation expression systems and existing transgenic mouse data [18]. Our *in vitro* experiments demonstrated that both PLG-A620T and PLG-G568R mutations maintained wild-type-level mRNA expression as shown by RT-qPCR, exhibited normal protein synthesis and secretion in WB and ELISA analyses, yet displayed significantly reduced enzymatic activity. These findings collectively establish a clear “conformational defect → functional impairment” pathogenic mechanism in human systems. Notably, this contrasts with the compensatory mRNA upregulation observed in PLG-A620T transgenic mice, a discrepancy we attribute to species-specific differences. The 22% non-conservative amino acid divergence between human and mouse PLG likely enhances mutation protein misfolding in murine endoplasmic reticulum (ER), triggering unfolded protein response-mediated mRNA upregulation. In contrast, human mutations achieve proper folding and secretion but retain catalytic defects. This comparative analysis highlights critical interspecies variation in protein quality control mechanisms and emphasizes the necessity of human-relevant models for translational research.

PLG deficiency presents ongoing clinical challenges, including heterogeneous diagnostic criteria and a lack of targeted therapies, with fresh frozen plasma remaining the primary treatment option in China due to the

absence of approved PLG-specific replacement therapies [19, 20]. The condition's thrombotic predisposition, likely mediated by impaired fibrinolytic capacity and defective clot clearance [21, 22], underscores the need for improved diagnostic strategies. Based on our findings, we recommend routine implementation of PLG genetic testing, especially for two key patient groups: those with family histories of hereditary PLG deficiency and individuals presenting with unexplained cerebral infarction. Establishing such screening protocols would enable early intervention to mitigate thrombotic risks.

Conclusions

This study identifies a novel compound heterozygous PLG mutation (p.Ala620Thr/p.Gly568Arg) as the molecular basis for type II deficiency-associated cerebral infarction. Structural and functional analyses demonstrate these mutations specifically impair protein function through conformational disruption rather than affecting biosynthesis or secretion. Currently, research on PLG remains insufficient, particularly in elucidating the intrinsic mechanisms linking PLG dysfunction to thrombotic cerebrovascular events. This study's exploration of these mechanisms offers potential biomarkers and interventional targets for early diagnosis and treatment strategies, while also further revealing potential associations between PLG dysfunction and thrombosis. However, the exact causative relationship between reduced PLG: A levels and cerebral ischemia has yet to be fully clarified, necessitating larger-scale and more systematic investigations to obtain more substantial supporting evidence.

Abbreviations

| | |
|---------------|---|
| PLG | Plasminogen |
| PLG:A | Plasminogen activity |
| PLG:Ag | PLG antigen |
| CSA | Chromogenic Substrate Assay |
| ELISA | Enzyme-linked immunosorbent assay |
| RT-qPCR | Quantitative real-time PCR |
| WB | Western blot |
| t-PA | Tissue-type plasminogen activator |
| u-PA | Urokinase-type plasminogen activator |
| ECM | Extracellular matrix |
| NTP | N-terminal peptide |
| SP | Serine protease |
| PC:A | Protein C activity |
| AT:A | Antithrombin III activity |
| PS:A | Protein S activity |
| PLG:Ag | Plasminogen antigen |
| PPP | Platelet-poor plasma |
| CLSI | Clinical and Laboratory Standards Institute |
| PCR | Polymerase chain reaction |
| TEG | Thromboelastography |
| ACMG | American College of Medical Genetics and Genomics |
| CDS | Coding sequence |
| HEK293T cells | Human embryonic kidney 293T cells |
| DMEM | Dulbecco's Modified Eagle Medium |
| FBS | Fetal bovine serum |
| PMSF | Phenylmethylsulfonyl fluoride |
| SDS-PAGE | Sodium dodecyl sulfate-polyacrylamide gel electrophoresis |
| PVDF | Polyvinylidene fluoride |

| | |
|------|------------------------------------|
| TBST | Tris-buffered saline with Tween-20 |
| ECL | Enhanced chemiluminescence |
| MRI | Magnetic resonance imaging |
| ER | Endoplasmic reticulum |

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13023-025-04122-3>.

Supplementary Material 1: Supplementary Fig. 1. TEG test results of the proband. (R: Reflects the overall activity of endogenous coagulation system factors; K: Mainly reflects the function of fibrinogen in the early stage of coagulation; Angle: Mainly reflects the overall function of fibrinogen in the coagulation process; MA: Mainly reflects the overall function of platelets (including aggregation, contraction and release, etc.); Cl: Comprehensive index of coagulation function; EPL: Indicator for predicting fibrinolytic function; LY30: Indicator for measuring fibrinolytic function)

Supplementary Material 2: Supplementary Fig. 2. Quantitative analysis of PLG protein in transfected HEK293T cell lysates was performed by ELISA. ("ns" indicates no significant difference, $p > 0.05$)

Supplementary Material 3: Supplementary Tab 1. RT-qPCR primer sequences for PLG and GAPDH

Acknowledgements

The authors would like to express their gratitude to all the study participants for their participation in this research.

Author contributions

Yifan Lu participated in data collection, analysis and manuscript drafting, and approved the submitted and final versions. Fengjiao Wang was responsible for collecting comprehensive patient information, including medical history and symptoms, and conducted in-depth clinical consultations on diagnosis and treatment plans. Dandan Yu and Haixiao Xie participated in data collection and analysis. Yanhui Jin and Mingshan Wang contributed to the conception and design of the study. Lihong Yang contributed to the conception and design of the study, approved the submitted and final versions, and provided support for publication. In addition, all authors gave final approval of the submitted article version.

Funding

This work was supported by the Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province (2022E10022) and the Zhejiang Provincial Medical and Health Science and Technology Plan (2024KY1268).

Data availability

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (KY2022-R193).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Published online: 15 December 2025

References

1. Keragala CB, Medcalf RL. Plasminogen: an enigmatic Zymogen. *Blood*. 2021;137(21):2881–9. <https://doi.org/10.1182/blood.202008951>.
2. Baker SK, Strickland S. A critical role for plasminogen in inflammation. *J Exp Med*. 2020;217(4):e20191865. <https://doi.org/10.1084/jem.20191865>.
3. Al-Ghafry M, Abou-Ismaïl MY, Acharya SS. Inherited disorders of the fibrinolytic pathway: pathogenic phenotypes and diagnostic considerations of extremely rare disorders. *Semin Thromb Hemost*. 2025;51(2):227–35. <https://doi.org/10.1055/s-0044-1789596>.
4. Collins PW, Whyte CS, de Lloyd L, Narwal A, Bell SF, Gill N, Collis RE, Jenkins PV, Mutch NJ. Acute obstetric coagulopathy is associated with excess plasmin generation and proteolysis of fibrinogen and factor V. *Blood Adv*. 2025;9(1):2751–62. <https://doi.org/10.1182/bloodadvances.2024015514>.
5. Zhao M, Hu L, Lin Z, Yue X, Zheng X, Piao M, Jin X, Piao L, Cui R, Liu M, Cheng XW. Plasminogen activator inhibitor 1 controls abdominal aortic aneurism formation via the modulation of TGF- β /Smad2/3 signaling in mice. *FASEB J*. 2025;39(9):e70562. <https://doi.org/10.1096/fj.202403133RR>.
6. Kusakabe Y, Matsumoto K, Tsuyuki T, Hayashi Y, Watanabe H. Baicalin target protein, Annexin A2, is a target of new antitumor drugs. *Sci Rep*. 2024;14(1):21814. <https://doi.org/10.1038/s41598-024-68528-y>.
7. Xia H, Zhang HY, Liu MN, et al. Phenotype and gene mutation analysis of a hereditary plasminogen deficiency family. *J Wenzhou Med Univ*. 2019;49(06):432–6. <https://doi.org/10.3969/j.issn.2095-9400.2019.06.009>.
8. Dönmez-Demir B, Celkan T, Sarper N, Deda G, Ince E, Çalişkan Ü, Öztürk G, Karagün B, Küpesiz A, Tokgöz H, Akar N, Özdağ H. Novel plasminogen gene mutations in Turkish patients with type I plasminogen deficiency. *Blood Coagulation Fibrinolysis: Int J Haemostasis Thromb*. 2016;27(6):637–44. <https://doi.org/10.1097/MBC.0000000000000383>.
9. Esselmani H, Mabrouki YA, Yassine A, Akhtar B, Lfakir A. The first Moroccan case of severe type II congenital plasminogen deficiency with ligneous conjunctivitis. *Ann Biol Clin*. 2022;80(1):81–3. <https://doi.org/10.1684/abc.2022.1707>.
10. Schuster V, Hügler B, Tefs K. Plasminogen deficiency. *J Thromb Haemostasis: JTH*. 2007;5(12):2315–22. <https://doi.org/10.1111/j.1538-7836.2007.02776.x>.
11. Anglés-Cano E, Rojas G. Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site. *Biol Chem*. 2002;383(1):93–9. <https://doi.org/10.1515/BC.2002.009>.
12. Cheng X, Wang M, Jiang M, Bhugul PA, Hao X, Yang L. A protein C and plasminogen compound heterozygous mutation and a compound heterozygote of protein C in two related Chinese families. *Blood Coagulation Fibrinolysis: Int J Haemostasis Thromb*. 2016;27(7):838–44. <https://doi.org/10.1097/MBC.0000000000000579>.
13. Fang J, Chopp M, Xin H, Zhang L, Wang F, Golembieski W, Zhang ZG, He L, Liu Z. Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice. *J Cereb Blood Flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism*. 2021;41(10):2583–92. <https://doi.org/10.1177/0271678X211007958>.
14. Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M, Invitae Clinical Genomics Group, Topper S. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. *Genetics in medicine: official journal of the American College of Medical Genetics*. 2017;19(10):1105–1117. <https://doi.org/10.1038/gim.2017.37>.
15. Aoki N, Moroi M, Sakata Y, Yoshida N, Matsuda M. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. *J Clin Invest*. 1978;61(5):1186–95. <https://doi.org/10.1172/JCI109034>.
16. Mhashilkar AM, Viswanatha T, Chibber BA, Castellino FJ. Breaching the conformational integrity of the catalytic triad of the Serine protease plasmin: localized disruption of a side chain of His-603 strongly inhibits the amidolytic activity of human plasmin. *Proc Natl Acad Sci USA*. 1993;90(11):5374–7. <https://doi.org/10.1073/pnas.90.11.5374>.
17. Chen X, Zou M, Lu C, Zhou R, Lou S, Wang Y, Ding H, Han Z, Hu B. Analysis of cerebral infarction caused by dysplasminogenemia in three pedigrees. *Front Genet*. 2023;14:1132654. <https://doi.org/10.3389/fgene.2023.1132654>.
18. Tashima Y, Banno F, Kita T, Matsuda Y, Yanamoto H, Miyata T. Plasminogen Tochigi mice exhibit phenotypes similar to wild-type mice under

- experimental thrombotic conditions. PLoS ONE. 2017;12(7):e0180981. <https://doi.org/10.1371/journal.pone.0180981>.
19. Tenbrock K, Lehmann S, Schradang S, Moran J. Replacement therapy with Glu-Plasminogen for the treatment of severe respiratory and auditory complications of congenital plasminogen deficiency. *Acta Haematol.* 2019;141(3):146–7. <https://doi.org/10.1159/000495336>.
 20. Nakar C, McDaniel H, Parker JM, Thibaudeau K, Thukral N, Shapiro AD. Case report: respiratory lesions successfully treated with intravenous plasminogen, human-tvmh, replacement therapy in four patients with plasminogen deficiency type 1. *Front Pediatr.* 2024;12:1465166. <https://doi.org/10.3389/fped.2024.1465166>.
 21. Granito M, Schmidt B. Orthomolecular nutritional therapy for plasminogen deficiency: report of a case that showed positive results. *Haemophilia: Official J World Federation Hemophilia.* 2015;21(2):e139–41. <https://doi.org/10.1111/hae.12609>.
 22. Song KS, Lee SM, Choi JR. Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis. *J Korean Med Sci.* 2003;18(2):167–70. <https://doi.org/10.3346/jkms.2003.18.2.167>.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.